Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Dec;16(6):645-50.
doi: 10.1111/j.1365-2125.1983.tb02235.x.

Dose tolerance to lorazepam develop with once weekly dosing?

Dose tolerance to lorazepam develop with once weekly dosing?

S E File et al. Br J Clin Pharmacol. 1983 Dec.

Abstract

The effect of once weekly administration of lorazepam (2.5 mg) to benzodiazepine-naive student volunteers was assessed in a number of performance tests and on self-ratings. Tolerance developed to the effects of lorazepam on finger-tapping and on self-ratings of dizziness. No tolerance was observed to the drug-induced impairment in a nonsense-syllable paired associate learning test or to the effects on self-ratings of sedation or on heart rate. It is suggested that the reduced impairment in the digit-symbol substitution test observed in weeks 2 and 3 of lorazepam treatment was due to a 'masked' practice effect rather than to tolerance. Test-retest correlation coefficients were calculated for all the tests used. The effect of lorazepam in each test was also correlated with its effect in the other tests. There were significant correlations in performance on placebo in the finger-tapping (r = 0.66), digit-symbol substitution (r = 0.94), symbol copying (r = 0.96) and nonsense-syllable learning (r = 0.74) tests. It is suggested that benzodiazepine experience should be given to drug-naive subjects before they are used in cross-over experiments that involve this class of compound, since the major change in impairment occurred between the first and second exposure to lorazepam.

PubMed Disclaimer

References

    1. Clin Pharmacol Ther. 1971 May-Jun;12(3):468-81 - PubMed
    1. J Nerv Ment Dis. 1975 Dec;161(6):399-414 - PubMed
    1. Br J Clin Pharmacol. 1979;7 Suppl 1:61S-67S - PubMed
    1. Acta Pharmacol Toxicol (Copenh). 1979 May;44(5):364-9 - PubMed
    1. Psychopharmacology (Berl). 1979;66(3):309-13 - PubMed

Publication types

LinkOut - more resources